Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 41, Issue 10, 2014, Pages 1231-1236

  Tanaka, Akira ^a   Sadahiro, Sotaro ^a   Suzuki, Toshiyuki ^a   Okada, Kazutake ^a   Saito, Gota ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Multikinase inhibitor; Regorafenib

Indexed keywords

REGORAFENIB;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INOPERABLE CANCER; LIVER INJURY; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84923342882     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Strumberg D, Scheulen ME, Schultheis B, et al: Regorafe- nib (BAY 73-4506) in advanced colorectal cancer: A phase I study. Br J Cancer 106(11): 1722-1727, 2012.
2. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (9863): 303-312, 2013.
3. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0.
4. Wilhelm SM, Carter C. Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (19): 7099-7109, 2004.
5. Dumas J, Smith R and Lowinger T: Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Devel 7 (5): 600- 616, 2004.
6. Waddell T and Cunningham D: Evaluation of regorafenib in colorectal cancer and GIST. Lancet 381(9863): 273-275, 2013.
7. Wilhelm S, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129 (1): 245-255, 2011.
8. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12(7): 1322-1331, 2013.
9. DeWit M, Boers-Doets C, Saettini A. et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer 22 (3): 837-846, 2014.
10. Zygulska AL, Krzemieniecki K and Sowa-Staszczak A: Hypothyroidism during treatment with tyrosine kinase inhibitors. Endokrynol Pol 63 (4): 302-306. 2012.
11. Clemons J, Gao D, Naam M, et at Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer 10 (4): 225-231, 2012.
12. Shah RR, Morganroth J and Shah DR: Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 36 (7): 491-503, 2013.
13. Sunakawa Y, Furuse J, Okusaka T, et at Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs 32(1): 104-112, 2014.
14. Gastrointestinal Stromal Tumor (GIST) 33 (7): 997-1000, 2006.
15. Grothey A, Sugrue MM, Purdie DM, et at Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26 (33): 5326-5334, 2008.
16. Bennouna J, Sastre J, Arnold D, et at Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147):a randomised phase 3 trial. Lancet Oncol 14(1): 29-37, 2013.
17. Heijmen L, Punt CJ, TerVoert EG, et at Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: A functional imaging approach. Invest New Drugs 31 (4): 881-890. 2013.
18. Zuniga RM, Torcuator R, Jain R, et at Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neuro- oncol 99(2): 237-242, 2010.
19. Mautner VF, Nguyen R, Knecht R, et at Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21 (11): 2294-2295, 2010.